The approval of Spravato for the monotherapy indication in TRD was supported by data from the randomized, double-blind, ...
Boing Boing on MSN2d
FDA approves J&J's patented psychedelic esketamine for depression without requiring you take other antidepressants with itOn Tuesday, the US Food and Drug Administration (FDA) approved Johnson & Johnson's hallucinogenic drug esketamine (brand name ...
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The expanded indication allows esketamine nasal spray to be used as a standalone treatment in adults with MDD who have not ...
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration approved Johnson & Johnson’s ketamine-based nasal spray, Spravato, as a ...
The FDA has approved esketamine (Spravato) nasal spray as a monotherapy for adults with treatment-resistant depression. This ...
Esketamine (Spravato; Johnson & Johnson) is now the first and only monotherapy for adults with major depressive disorder (MDD ...
The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
Because it is still awaiting approval, Medicare does not typically cover the use of ketamine infusion for treating mental ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback